Clinical Trial Search

Primary: Weekly Change From Baseline in the 24-Hour Average Pain Rating Using an 11-Point Numerical Likert Scale Patient Diary — -0.36; -0.84; -0.95; -1.54 units on a scale…

Primary: Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis — 17.08; 17.30; -2.25; -4.92 units on a scale — p=<0.001

Primary: Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC) — 54.2; 48.4; 51.5; 50.2 Percent predicted FVC

Primary: Flu-like-syndrome — 17.4; 15.8; 31.1 Percentage of participants

Primary: Change From Baseline in 12-minute Walk Test at 24 Weeks — 109; 26 meters — p=0.025

Primary: Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years — -30; -30 ml/year — p=0.9524

Primary: Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC) — 5.85; 4.17 Months — p=.0003

Primary: Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End — 67.4; 36.3; 17.4 Percent — p=<0.001

Primary: Overall Survival (OS) — 16.39; 15.64 months — p=.1162

Primary: Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value — 113; 100; 105; 92 subjects

Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03

Primary: Clinical Resolution — 167; 147 Participants

Primary: Local Catheter Site Infection (LCSI) — 50; 70 Events — p=0.082

Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis — 90; 63 Participants

Primary: Change From Baseline in Serum Phosphorus Levels at 4 Weeks — -1.73; -1.44 mg/dL — p=0.1130